Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 77Thoracic 29Head & Neck 12Lymphoid 6Gynecologic 5Other solid neoplasm 3Genitourinary 3CNS 3Breast 3Tumor-Agnostic 2Endocrine 2Sarcoma 1Other neoplasm 1NET 1Myeloid 1Dermatologic 1

Conditions

Neuroendocrine Tumors 1Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 4lanreotide 3Temozolomide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3(177)Lu-DOTA-EB-TATE 3anlotinib 2Positron Emission Tomography Computed Tomography 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Metformin 2Everolimus 2Etoposide 2Cisplatin 2Capecitabine 2Biopsy 2surufatinib 1sintilimab 1regorafenib 1recombinant interferon alpha 2b-like protein 1pembrolizumab 1gallium Ga 68 dotatate 1copper dotatate CU-64 1cabozantinib 1amino-acid, glucose, and electrolyte solution 1Yttrium-90 1Tomography, Emission-Computed, Single-Photon 1Thalidomide 1Tegafur 1Surgical Procedures, Operative 1Somatostatin 1Rose Bengal B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × sintilimab × NET × Clear all
NCT05113355 2021-11-24

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Peking Union Medical College Hospital

Phase 2 Unknown
23 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡